The present invention provides a compound represented by the following formula (I) or its pharmaceutically acceptable salt:
[wherein, R
1
represents optionally substituted C
1-4
alkyl, n shows integer of 1 to 4, R
2
represents optionally substituted C
1-4
alkyl or hydrogen atom, R
3
represents optionally substituted C
1-4
alkyl, R
4a
, R
4b
, R
4c
, and R
4d
, similarly or differently, represent optionally substituted C
6-14
aryl, optionally substituted C
1-4
alkyl, or hydrogen atom and the like, A represents optionally substituted C
6-14
aryl or optionally substituted 5 to 11 membered heteroaryl].
The present invention relates to substituted aryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.
Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods of treating, inhibiting, and/or abatement of cognitive decline and/or Alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods of preparing the compounds/compositions of the invention.
The present invention relates to substituted aryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.